Citations 2
Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma
LaCasce, Ann S. , Bociek, R. Gregory , Sawas, Ahmed , Agura, Edward, Matous, Jeffrey, Ansell, Stephen M. , Crosswell, Howland E. , Islas‐Ohlmayer, Miguel, Behler, Caroline, Cheung, Eric, Forero‐Torres, Andres , O’Connor, Owen A. , Josephson, Neil C. , Advani, Ranjana H. , Advani, Ranjana H , Caimi, Paolo F. , Vose, Julie M. , Wang, Yinghui
British Journal of Haematology | February 12, 2020 | Volume: 189 | Issue: 3 | Pages: No page available
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
LaCasce, Ann S. , Bociek, R. Gregory , Sawas, Ahmed , Caimi, Paolo, Agura, Edward, Matous, Jeffrey, Ansell, Stephen M. , Crosswell, Howland E. , Islas‐Ohlmayer, Miguel, Behler, Caroline, Cheung, Eric, Forero‐Torres, Andres , O’Connor, Owen A. , Josephson, Neil C. , Advani, Ranjana H. , Advani, Ranjana H , Vose, Julie M. , Wang, Yinghui
Blood | April 27, 2018 | Volume: 132 | Issue: 1 | Pages: 40-48
Key PointsThe outpatient BV and bendamustine regimen is highly active as first salvage therapy in relapsed/refractory HL, with manageable toxicity. The CR rate of 73.6% exceeded those reported for standard chemotherapy regimens, and post-ASCT outcomes generally appeared excellent.